Disclosure Of First-Time Adoption [Text Block]

Sopharma AD - Filing #6139233

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2023-12-31
2022-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
753 626 BGN
395 897 BGN
1 857 BGN
29 328 BGN
15 294 BGN
172 591 BGN
1 154 BGN
57 452 BGN
738 332 BGN
506,000 BGN
196 759 BGN
68 628 BGN
716 634 BGN
35 263 BGN
12 488 BGN
11 976 BGN
509 869 BGN
52 203 BGN
134 798 BGN
4 745 BGN
704 658 BGN
560,000 BGN
50 284 BGN
444 634 BGN
66 201 BGN
36 788 BGN
658 868 BGN
1 644 BGN
12 512 BGN
646 975 BGN
11 893 BGN
682,000 BGN
134 798 BGN
Comprehensive income
103 789 BGN
30,000 BGN
94 589 BGN
3 591 BGN
99 976 BGN
3 813 BGN
1 766 BGN
70 465 BGN
72 476 BGN
5 355 BGN
892,000 BGN
1 047 BGN
65 110 BGN
5 427 BGN
Profit (loss)
99 874 BGN
95 977 BGN
3 897 BGN
95 977 BGN
76 333 BGN
71 121 BGN
5 212 BGN
71 121 BGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.